Skip to main content
Livzon Pharmaceutical Group Inc. logo

Livzon Pharmaceutical Group Inc. — Investor Relations & Filings

Ticker · 1513 ISIN · CNE100001QV5 LEI · 529900Y4GWTVVTORJ443 HKEX Manufacturing
Open in API
Filings indexed 2,608 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country CN China
Listing HKEX 1513

About Livzon Pharmaceutical Group Inc.

http://www.livzon.com.cn

Livzon Pharmaceutical Group Inc., established in 1985, is a comprehensive pharmaceutical enterprise integrating the research, development, production, and sales of finished pharmaceutical products and Active Pharmaceutical Ingredients (API). The Group maintains a strong focus on therapeutic areas such as digestive health, reproductive endocrinology, and immune diseases. Committed to product quality, Livzon implements a rigorous quality management system to ensure the effectiveness, safety, and stability of its portfolio.

Recent filings

Filing Released Lang Actions
关于参加深圳证券交易所深研发求精进·积蓄医药成长新动能2025年度集体业绩说明会的公告
Regulatory Filings Classification · 85% confidence The document is an announcement (“公告”) that the company will participate in a collective performance briefing organized by the Shenzhen Stock Exchange, giving logistical details (time, location, participants) and how investors can submit questions. No financial statements, presentation materials, or substantive analysis are included, nor is the actual report attached. This is a general regulatory announcement and does not fit any specific category (e.g., it is not the actual investor presentation, not a transcript, nor a report publication notice). Hence it falls under the fallback category Regulatory Filings (RNS).
2026-05-14 Chinese
关于为子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of guarantees provided by the parent company to its subsidiary. It details the guarantee agreements signed with banks, the amounts, terms, and the financial status of the guaranteed party. The document is a formal disclosure of financing guarantees and related risk information, not a financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital/financing updates related to guarantees and credit support. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and is a standalone announcement, not a report publication or certification.
2026-05-08 Chinese
H股公告：证券变动月报表
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report submitted to the Hong Kong Stock Exchange (HKEX) under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, public float confirmations, and other share-related information for the month ending April 30, 2026. The document is structured as a regulatory compliance report on share capital and public float status, not a financial report, earnings release, or management discussion. It is not an announcement of voting results, board changes, or financing updates. The document is a regulatory filing related to share capital and public float disclosures required by HKEX rules. Given the content and purpose, the most appropriate classification is Regulatory Filings (RNS). The document length is 4144 characters, which is relatively short but contains substantive regulatory information rather than just an announcement of a report publication, so it is not RPA. There is no indication of officer certification or attestation only, so it is not RNS due to certification. Therefore, the best fit is RNS as a general regulatory announcement about share capital and public float compliance.
2026-05-06 Chinese
VOLUNTARY ANNOUNCEMENT THE NOTICE OF DRUG CLINICAL TRIAL APPROVAL OF JP-1366 TABLET
Regulatory Filings Classification · 86% confidence The document is a voluntary announcement regarding the approval of a clinical trial by a regulatory authority (NMPA). It is not a financial report, dividend notice, or detailed investor presentation, nor is it an AGM or earnings release. It does not fit any specialized category (e.g., M&A, ESG, management change). Therefore it falls under the general “Regulatory Filings” (RNS) fallback category for miscellaneous corporate regulatory announcements.
2026-04-10 English
Date of Board Meeting
Regulatory Filings Classification · 80% confidence The document is a brief announcement by Livzon Pharmaceutical Group Inc. regarding the date of a Board meeting to consider and approve its unaudited quarterly results. It does not contain the results themselves nor any change of board members, dividend information, or any detailed report. It simply notifies the market of an upcoming board meeting, which does not match any more specific category. Therefore it falls under the fallback category of general regulatory announcements (RNS).
2026-04-08 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 80% confidence The document is extremely short and merely states that an announcement has been published elsewhere (Chinese section of the website) without providing any substantive content or detailed financial information. This fits the ‘Report Publication Announcement’ category, which covers notices that reports or announcements have been published or attached. Therefore, the appropriate classification is RPA.
2026-04-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.